Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:vemurafenib
go back to main search page
Accession:CHEBI:63637 term browser browse the term
Definition:A pyrrolopyridine that is 1H-pyrrolo[2,3-b]pyridine which is substituted at position 5 by a p-chlorophenyl group and at positions 3 by a 3-amino-2,6-difluorobenzoyl group, the amino group of which has undergone formal condensation with propane-1-sulfonic acid to give the corresponding sulfonamide. An inhibitor of BRAF and other kinases.
Synonyms:exact_synonym: N-(3-{[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl}-2,4-difluorophenyl)propane-1-sulfonamide
 related_synonym: Formula=C23H18ClF2N3O3S;   InChI=1S/C23H18ClF2N3O3S/c1-2-9-33(31,32)29-19-8-7-18(25)20(21(19)26)22(30)17-12-28-23-16(17)10-14(11-27-23)13-3-5-15(24)6-4-13/h3-8,10-12,29H,2,9H2,1H3,(H,27,28);   InChIKey=GPXBXXGIAQBQNI-UHFFFAOYSA-N;   SMILES=C(CC)S(NC1=CC=C(C(=C1F)C(C=2C3=C(N=CC(=C3)C=4C=CC(=CC4)Cl)NC2)=O)F)(=O)=O;   Zelboraf;   vemurafenibum
 xref: CAS:918504-65-1;   Drug_Central:4185;   KEGG:D09996;   LINCS:LSM-1068
 xref_mesh: MESH:C551177
 xref: PDBeChem:032;   PMID:21609436;   PMID:21639808;   PMID:22028422;   PMID:22037033;   PMID:22083257;   PMID:22180495;   Patent:WO2010114928;   Reaxys:12833468;   Wikipedia:Vemurafenib


show annotations for term's descendants           Sort by:
 
vemurafenib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acaca acetyl-CoA carboxylase alpha multiple interactions ISO [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA] CTD PMID:29950559 NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457
JBrowse link
G Acly ATP citrate lyase multiple interactions ISO [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA] CTD PMID:29950559 NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of AKT1 mRNA CTD PMID:27169980 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of APAF1 mRNA CTD PMID:27169980 NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
JBrowse link
G Bad BCL2-associated agonist of cell death multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of BAD protein CTD PMID:27169980 NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of BAX protein CTD PMID:27169980 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bbc3 Bcl-2 binding component 3 multiple interactions ISO [BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein] CTD PMID:27689874 NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of BCL2 mRNA CTD PMID:27169980 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of BCL2L1 mRNA CTD PMID:27169980 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions ISO [BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein] CTD PMID:27689874 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of BIRC5 mRNA CTD PMID:27169980 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase decreases activity
affects response to substance
multiple interactions
increases response to substance
ISO Vemurafenib results in decreased activity of BRAF protein; Vemurafenib results in decreased activity of BRAF protein mutant form
BRAF protein affects the susceptibility to Vemurafenib
[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein; [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA; [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA; [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of SLC5A5 mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TSHR mRNA; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased expression of TNFRSF10B protein; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased expression of CD70 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BBC3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BCL2L11 protein; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BBC3 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in increased expression of BCL2L11 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; A-1155463 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]]; ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]]; betulin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; betulin affects the reaction [BRAF protein affects the susceptibility to Vemurafenib]; BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]; BRAF protein affects the reaction [Vemurafenib results in decreased expression of CD70 protein]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK1 protein]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK3 protein]; CCND1 protein inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; fatostatin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; fatostatin affects the reaction [BRAF protein affects the susceptibility to Vemurafenib]; MAPK1 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; MAPK3 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACACA mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of ACLY mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK3 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of BRAF protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] affects the reaction [TSHB protein affects the expression of SLC5A5 mRNA]]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of SLC5A5 mRNA]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TSHR mRNA]
BRAF gene mutant form results in increased susceptibility to vemurafenib; BRAF protein mutant form results in increased susceptibility to vemurafenib
BRAF protein affects the susceptibility to Vemurafenib; BRAF protein mutant form affects the susceptibility to Vemurafenib
CTD PMID:20823850 PMID:21185263 PMID:23237741 PMID:24859340 PMID:26640592 More... NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]] CTD PMID:27222248 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp8 caspase 8 multiple interactions ISO [KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]] CTD PMID:27222248 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 increases secretion
decreases response to substance
increases expression
ISO vemurafenib results in increased secretion of CCL2 protein
CCL2 protein results in decreased susceptibility to vemurafenib
vemurafenib results in increased expression of CCL2 mRNA
CTD PMID:26684239 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Ccnb1 cyclin B1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of CCNB1 mRNA CTD PMID:27169980 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression
ISO CCND1 protein inhibits the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]
vemurafenib results in decreased expression of CCND1 protein
CTD PMID:26978007 PMID:27087167 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Ccne1 cyclin E1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of CCNE1 mRNA CTD PMID:27169980 NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
JBrowse link
G Cd40 CD40 molecule multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of CD40 protein CTD PMID:27169980 NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
JBrowse link
G Cd40lg CD40 ligand multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of CD40LG protein CTD PMID:27169980 NCBI chr  X:135,127,119...135,138,302
Ensembl chr  X:135,126,969...135,138,306
JBrowse link
G Cd70 Cd70 molecule decreases expression
multiple interactions
ISO vemurafenib results in decreased expression of CD70 protein
[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in decreased expression of CD70 protein; BRAF protein affects the reaction [vemurafenib results in decreased expression of CD70 protein]
CTD PMID:26828592 NCBI chr 9:2,006,563...2,009,715
Ensembl chr 9:2,006,563...2,009,715
JBrowse link
G Cdc25a cell division cycle 25A multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of CDC25A mRNA CTD PMID:27169980 NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701
JBrowse link
G Cdc25c cell division cycle 25C multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of CDC25C mRNA CTD PMID:27169980 NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
JBrowse link
G Cdk4 cyclin-dependent kinase 4 decreases expression ISO vemurafenib results in decreased expression of CDK4 protein CTD PMID:27087167 NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of CDKN1B protein CTD PMID:27169980 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
JBrowse link
G Chek1 checkpoint kinase 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of CHEK1 mRNA CTD PMID:27169980 NCBI chr 8:36,420,565...36,443,477 JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions ISO [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of DDIT3 protein; DDIT3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein] CTD PMID:27222248 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Dio3 iodothyronine deiodinase 3 decreases expression ISO vemurafenib results in decreased expression of DIO3 CTD PMID:26825960 NCBI chr 6:129,285,747...129,287,608
Ensembl chr 6:129,285,749...129,286,660
JBrowse link
G E2f1 E2F transcription factor 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of E2F1 mRNA CTD PMID:27169980 NCBI chr 3:143,064,535...143,075,362 JBrowse link
G Ehf ets homologous factor multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of EHF mRNA CTD PMID:27169980 NCBI chr 3:89,639,845...89,680,061
Ensembl chr 3:89,641,833...89,679,997
JBrowse link
G Elk1 ETS transcription factor ELK1 multiple interactions ISO [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of ELK1 protein; ELK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein] CTD PMID:27222248 NCBI chr  X:1,138,826...1,155,713
Ensembl chr  X:1,139,756...1,155,713
JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions ISO [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of ERN1 protein CTD PMID:27222248 NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
JBrowse link
G Ezh2 enhancer of zeste 2 polycomb repressive complex 2 subunit multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of EZH2 mRNA CTD PMID:27169980 NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362
JBrowse link
G Faslg Fas ligand multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of FASLG protein CTD PMID:27169980 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
JBrowse link
G Fasn fatty acid synthase multiple interactions ISO [BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the expression of FASN mRNA] CTD PMID:29950559 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
JBrowse link
G Hgf hepatocyte growth factor multiple interactions ISO [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]; A-1155463 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]]; ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]] CTD PMID:27689874 NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha increases expression ISO vemurafenib results in increased expression of HIF1A mRNA CTD PMID:26684239 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
JBrowse link
G Hspa1a heat shock protein family A (Hsp70) member 1A decreases response to substance ISO HSPA1A protein results in decreased susceptibility to vemurafenib CTD PMID:26984758
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions ISO [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of HSPA5 protein CTD PMID:27222248 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
JBrowse link
G Htra1 HtrA serine peptidase 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of HTRA1 protein CTD PMID:27169980 NCBI chr 1:185,497,815...185,547,380
Ensembl chr 1:185,497,735...185,547,379
JBrowse link
G Igfbp1 insulin-like growth factor binding protein 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of IGFBP1 protein CTD PMID:27169980 NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
JBrowse link
G Igfbp2 insulin-like growth factor binding protein 2 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of IGFBP2 protein CTD PMID:27169980 NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937
JBrowse link
G Igfbp6 insulin-like growth factor binding protein 6 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of IGFBP6 protein CTD PMID:27169980 NCBI chr 7:133,276,309...133,280,944
Ensembl chr 7:133,276,234...133,280,966
JBrowse link
G Kras KRAS proto-oncogene, GTPase affects response to substance
multiple interactions
ISO KRAS protein mutant form affects the susceptibility to vemurafenib
[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]; [KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]; [KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of DDIT3 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of ERN1 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of HSPA5 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B mRNA; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of ELK1 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein; [KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]; AZD 6244 inhibits the reaction [KRAS protein mutant form affects the susceptibility to vemurafenib]; Dactinomycin inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B mRNA]; DDIT3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; ELK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; MAPK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; MAPK3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein]; vemurafenib promotes the reaction [KRAS protein mutant form results in increased expression of TNFRSF10B mRNA]; vemurafenib promotes the reaction [KRAS protein mutant form results in increased expression of TNFRSF10B protein]; vemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK1 protein]; vemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK3 protein]
CTD PMID:27222248 NCBI chr 4:178,185,418...178,218,484 JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation
increases phosphorylation
ISO [BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK1 protein; [KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein; [NRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein; [YAP1 protein mutant form results in decreased susceptibility to Vemurafenib] inhibits the reaction [Vemurafenib results in decreased phosphorylation of MAPK1 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK1 protein]; MAPK1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased expression of TNFRSF10B protein]; MAPK1 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK1 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK1 protein]; Vemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK1 protein]
vemurafenib results in decreased phosphorylation of MAPK1 protein
vemurafenib results in increased phosphorylation of MAPK1 protein
CTD PMID:26640592 PMID:26668268 PMID:26751190 PMID:26828592 PMID:26978007 More... NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation
multiple interactions
increases phosphorylation
ISO vemurafenib results in decreased phosphorylation of MAPK3 protein
[BRAF protein mutant form affects the susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [BRAF protein mutant form results in increased susceptibility to Vemurafenib] which results in decreased phosphorylation of MAPK3 protein; [KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein; [NRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein; [YAP1 protein mutant form results in decreased susceptibility to Vemurafenib] inhibits the reaction [Vemurafenib results in decreased phosphorylation of MAPK3 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein]; BRAF protein mutant form inhibits the reaction [Vemurafenib results in increased phosphorylation of MAPK3 protein]; MAPK3 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased expression of TNFRSF10B protein]; MAPK3 protein modified form inhibits the reaction [BRAF protein mutant form results in increased susceptibility to Vemurafenib]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the phosphorylation of MAPK3 protein]; Vemurafenib inhibits the reaction [BRAF protein mutant form results in increased phosphorylation of MAPK3 protein]; Vemurafenib promotes the reaction [KRAS protein mutant form results in increased phosphorylation of MAPK3 protein]
vemurafenib results in increased phosphorylation of MAPK3 protein
CTD PMID:26640592 PMID:26668268 PMID:26751190 PMID:26828592 PMID:26978007 More... NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of MCL1 mRNA CTD PMID:27169980 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions ISO [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BBC3 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [[BRAF protein mutant form results in increased susceptibility to vemurafenib] which results in increased expression of BCL2L11 protein]; [MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]; A-1155463 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]]; ABT-737 inhibits the reaction [[MET protein affects the susceptibility to HGF protein] affects the reaction [BRAF protein mutant form results in increased susceptibility to vemurafenib]] CTD PMID:27689874 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876
JBrowse link
G Mitf melanocyte inducing transcription factor affects expression ISO vemurafenib affects the expression of MITF protein CTD PMID:26640592 NCBI chr 4:130,409,020...130,621,145
Ensembl chr 4:130,409,217...130,621,145
JBrowse link
G Mlana melan-A increases expression ISO vemurafenib results in increased expression of MLANA mRNA; vemurafenib results in increased expression of MLANA protein CTD PMID:26640592 NCBI chr 1:227,469,537...227,483,343
Ensembl chr 1:227,469,537...227,483,343
JBrowse link
G Mmp1 matrix metallopeptidase 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of MMP1 mRNA CTD PMID:27169980 NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor decreases expression
multiple interactions
ISO vemurafenib results in decreased expression of MYC protein
(+)-JQ1 compound promotes the reaction [vemurafenib results in decreased expression of MYC protein]; [YAP1 protein mutant form results in decreased susceptibility to vemurafenib] inhibits the reaction [vemurafenib results in decreased expression of MYC protein]; vemurafenib promotes the reaction [(+)-JQ1 compound results in decreased expression of MYC protein]
CTD PMID:26284497 PMID:26668268 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Nras NRAS proto-oncogene, GTPase affects response to substance
multiple interactions
ISO NRAS protein mutant form affects the susceptibility to vemurafenib
[NRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased expression of TNFRSF10B protein; [NRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK1 protein; [NRAS protein mutant form affects the susceptibility to vemurafenib] which results in increased phosphorylation of MAPK3 protein
CTD PMID:27222248 NCBI chr 2:190,582,885...190,593,509
Ensembl chr 2:190,582,918...190,591,626
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]; AZD 6244 inhibits the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]] CTD PMID:27222248 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
JBrowse link
G Pmel premelanosome protein increases expression ISO vemurafenib results in increased expression of PMEL mRNA; vemurafenib results in increased expression of PMEL protein CTD PMID:26640592 NCBI chr 7:1,138,202...1,148,735
Ensembl chr 7:1,138,586...1,148,746
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 decreases expression ISO vemurafenib results in decreased expression of PTGS2 protein CTD PMID:27087167 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase multiple interactions ISO RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP3 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of CASP8 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] promotes the reaction [TNFRSF10B protein results in increased cleavage of PARP1 protein]]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased expression of TNFRSF10B protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK1 protein]; RAF1 protein affects the reaction [[KRAS protein mutant form affects the susceptibility to Vemurafenib] which results in increased phosphorylation of MAPK3 protein] CTD PMID:27222248 NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
JBrowse link
G Slc5a5 solute carrier family 5 member 5 multiple interactions ISO [BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of SLC5A5 mRNA; [TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA; [vemurafenib co-treated with vorinostat] results in increased expression of SLC5A5 protein; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA]; BRAF protein mutant form affects the reaction [vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA]]; TSHB protein promotes the reaction [[vemurafenib co-treated with vorinostat] results in increased expression of SLC5A5 protein]; vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] affects the reaction [TSHB protein affects the expression of SLC5A5 mRNA]]; vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of SLC5A5 mRNA]; vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of SLC5A5 mRNA] CTD PMID:26751190 NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 decreases cleavage
decreases expression
multiple interactions
ISO Vemurafenib results in decreased cleavage of SREBF1 protein
Vemurafenib results in decreased expression of SREBF1 mRNA alternative form
[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein; betulin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]; fatostatin affects the reaction [BRAF protein affects the reaction [Vemurafenib results in decreased cleavage of SREBF1 protein]]; trametinib affects the reaction [[BRAF protein affects the susceptibility to Vemurafenib] which affects the cleavage of SREBF1 protein]
CTD PMID:29950559 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
JBrowse link
G Tg thyroglobulin multiple interactions ISO [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TG mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA] CTD PMID:26751190 NCBI chr 7:98,418,293...98,603,210
Ensembl chr 7:98,418,293...98,603,210
JBrowse link
G Tgfa transforming growth factor alpha multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of TGFA mRNA CTD PMID:27169980 NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in decreased expression of TGFB1 mRNA CTD PMID:27169980 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of TNF protein CTD PMID:27169980 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnfrsf10b TNF receptor superfamily member 10b multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of TNFRSF10A protein CTD PMID:27169980 NCBI chr15:44,839,818...44,867,582 JBrowse link
G Tnfrsf1b TNF receptor superfamily member 1B multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of TNFRSF1B protein CTD PMID:27169980 NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206
JBrowse link
G Tnfrsf21 TNF receptor superfamily member 21 multiple interactions ISO [(+)-JQ1 compound co-treated with vemurafenib] results in increased expression of TNFRSF21 protein CTD PMID:27169980 NCBI chr 9:17,879,156...17,954,085
Ensembl chr 9:17,879,156...17,954,085
JBrowse link
G Tnfrsf26 tumor necrosis factor receptor superfamily, member 26 multiple interactions ISO [(+)-JQ1 compound co-treated with Vemurafenib] results in increased expression of TNFRSF10D protein CTD PMID:27169980 NCBI chr 1:198,802,513...198,824,049
Ensembl chr 1:198,802,971...198,823,418
JBrowse link
G Tpo thyroid peroxidase multiple interactions ISO [BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] which affects the expression of TPO mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA] CTD PMID:26751190 NCBI chr 6:46,698,402...46,768,199
Ensembl chr 6:46,698,414...46,768,199
JBrowse link
G Tshb thyroid stimulating hormone subunit beta multiple interactions ISO [TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA; [TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]]; BRAF protein mutant form affects the reaction [Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA]]; TSHB protein promotes the reaction [[Vemurafenib co-treated with Vorinostat] results in increased expression of SLC5A5 protein]; Vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to Vemurafenib] affects the reaction [TSHB protein affects the expression of SLC5A5 mRNA]]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of SLC5A5 mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TG mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TPO mRNA]; Vorinostat affects the reaction [[TSHB protein co-treated with Vemurafenib] affects the expression of TSHR mRNA] CTD PMID:26751190 NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
JBrowse link
G Tshr thyroid stimulating hormone receptor multiple interactions ISO [BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of TSHR mRNA; [TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA; BRAF protein mutant form affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA]; BRAF protein mutant form affects the reaction [vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA]]; vorinostat affects the reaction [[BRAF protein mutant form affects the susceptibility to vemurafenib] which affects the expression of TSHR mRNA]; vorinostat affects the reaction [[TSHB protein co-treated with vemurafenib] affects the expression of TSHR mRNA] CTD PMID:26751190 NCBI chr 6:110,341,585...110,475,297
Ensembl chr 6:110,341,581...110,474,538
JBrowse link
G Tyr tyrosinase increases expression ISO Vemurafenib results in increased expression of TYR mRNA; Vemurafenib results in increased expression of TYR protein CTD PMID:26640592 NCBI chr 1:141,115,036...141,210,207
Ensembl chr 1:141,115,036...141,210,207
JBrowse link
G Tyrp1 tyrosinase-related protein 1 increases expression ISO vemurafenib results in increased expression of TYRP1 protein CTD PMID:26640592 NCBI chr 5:95,280,982...95,299,516
Ensembl chr 5:95,280,982...95,299,516
JBrowse link
G Wwtr1 WW domain containing transcription regulator 1 affects localization ISO vemurafenib affects the localization of WWTR1 protein CTD PMID:26668268 NCBI chr 2:141,651,159...141,766,919
Ensembl chr 2:141,648,108...141,766,968
JBrowse link
G Yap1 Yes1 associated transcriptional regulator multiple interactions
affects localization
decreases response to substance
ISO [YAP1 protein mutant form results in decreased susceptibility to vemurafenib] inhibits the reaction [vemurafenib results in decreased expression of MYC protein]; [YAP1 protein mutant form results in decreased susceptibility to vemurafenib] inhibits the reaction [vemurafenib results in decreased phosphorylation of MAPK1 protein]; [YAP1 protein mutant form results in decreased susceptibility to vemurafenib] inhibits the reaction [vemurafenib results in decreased phosphorylation of MAPK3 protein]
vemurafenib affects the localization of YAP1 protein
CTD PMID:26668268 NCBI chr 8:5,095,705...5,166,808
Ensembl chr 8:5,095,722...5,167,010
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19812
    role 19761
      application 19471
        pharmaceutical 19319
          drug 19319
            antineoplastic agent 17316
              vemurafenib 74
Path 2
Term Annotations click to browse term
  CHEBI ontology 19812
    subatomic particle 19811
      composite particle 19811
        hadron 19811
          baryon 19811
            nucleon 19811
              atomic nucleus 19811
                atom 19811
                  main group element atom 19708
                    p-block element atom 19708
                      chalcogen 19460
                        oxygen atom 19436
                          oxygen molecular entity 19436
                            hydroxides 19175
                              oxoacid 18488
                                chalcogen oxoacid 11491
                                  sulfur oxoacid 11099
                                    sulfonic acid 7367
                                      sulfonic acid derivative 7367
                                        sulfonamide 3193
                                          vemurafenib 74
paths to the root